Feng Du, Zhiwei Sun, Jun Jia, Ying Yang, Jing Yu, Youwu Shi, Bo Jia, Jiuda Zhao, Xiaodong Zhang*. Development and Validation of an Individualized Nomogram for Predicting Survival in Patients with Esophageal Carcinoma after Resection,Journal of Cancer,2020,11(14), 4023-4029

Ying Yang, Jun Jia, Zhiwei Sun, Chuanling Liu, Yanjie Xiao, Jing Yu, Feng Du, Xiaodong Zhang*. Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma,Cancer Management and Research,2020,12(3), 2177–2184

Zhiwei Sun, Jun Jia, Feng Du, Ying Yang, Chuanling Liu, Yanjie Xiao, Jing Yu, Xiaodong Zhang*. Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy,Translational Cancer Research,2020，8（8）, 2680-2690

孙志伟，贾军，杜丰，刘传玲，余靖，杨颖，肖艳洁，张晓东*. 不可手术切除的局部进展期或转移性胃癌患者一线化疗前血液肿瘤标志物在预后评估中的价值,中国普通外科杂志,2019;28(8),1023-1030

王方,贾军,杨颖,余靖,孙志伟,刘传玲,肖艳洁,杜丰,史幼梧,张晓东*. 淋巴结转移率与食管鳞癌根治术后预后及术后辅助化疗的关系,中华消化外科杂志,2019;18(6),549-555

Xiaodong Zhang#*, Jun Jia#, Ming Lu#, Xicheng Wang, Jifang Gong, Jie Li, Jian Li, Yan Li, Xiaotian Zhang, Zhihao Lu, Jun Zhou, Jing Yu, Zhiwei Sun, Ying Yang, Chuanling Liu, Yanjie Xiao, Lin Shen*. Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study,JOURNAL OF CANCER,2019; 10(6): 1409-1416

消化道肿瘤临床与基础研究

甲磺酸阿帕替尼联合伊立替康治疗一线化疗失败晚期食管鳞癌的II期临床研究, 参加者, 2017.2.1～2021.12.31, CSCO—恒瑞肿瘤研究基金

阿帕替尼片联合伊立替康递增剂量二线治疗晚期食管鳞癌的临床和基础研究, 课题负责人, 2016.1.1～2018.12.31, 希思科(CSCO)- 恒瑞肿瘤研究基金

抗EGFR靶向治疗食管鳞癌疗效预测分子标志物的筛选与临床评价, 课题负责人, 2016.1.1～2018.12.31, 首都卫生发展科研专项基金，首发2016-2-2152